High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma. / Jensen, Jakob Schmidt; Christensen, Julie Thor; Håkansson, Katrin; Zamani, Martin; Vogelius, Ivan R; Löfgren, Johan; Fischer, Babara Malene; Friborg, Jeppe; von Buchwald, Christian; Rasmussen, Jacob Høygaard.

I: European Journal of Nuclear Medicine and Molecular Imaging, Bind 47, 2020, s. 1039–1045.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jensen, JS, Christensen, JT, Håkansson, K, Zamani, M, Vogelius, IR, Löfgren, J, Fischer, BM, Friborg, J, von Buchwald, C & Rasmussen, JH 2020, 'High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma', European Journal of Nuclear Medicine and Molecular Imaging, bind 47, s. 1039–1045. https://doi.org/10.1007/s00259-019-04572-5

APA

Jensen, J. S., Christensen, J. T., Håkansson, K., Zamani, M., Vogelius, I. R., Löfgren, J., Fischer, B. M., Friborg, J., von Buchwald, C., & Rasmussen, J. H. (2020). High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 47, 1039–1045. https://doi.org/10.1007/s00259-019-04572-5

Vancouver

Jensen JS, Christensen JT, Håkansson K, Zamani M, Vogelius IR, Löfgren J o.a. High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47:1039–1045. https://doi.org/10.1007/s00259-019-04572-5

Author

Jensen, Jakob Schmidt ; Christensen, Julie Thor ; Håkansson, Katrin ; Zamani, Martin ; Vogelius, Ivan R ; Löfgren, Johan ; Fischer, Babara Malene ; Friborg, Jeppe ; von Buchwald, Christian ; Rasmussen, Jacob Høygaard. / High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma. I: European Journal of Nuclear Medicine and Molecular Imaging. 2020 ; Bind 47. s. 1039–1045.

Bibtex

@article{de01c8c895084b0db00e3c894492df4d,
title = "High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma",
abstract = "BACKGROUND: The purpose of this study was to investigate if FDG uptake metrics in primary tumor and lymph node metastases in patients with oropharyngeal squamous cell carcinoma (OPSCC) has a prognostic value beyond UICC8 staging in a multiple endpoint model.METHODS: Patients with OPSCC treated with primary radiotherapy at Rigshospitalet in the period 2010-2017 were included. All patients had a pretreatment FDG PET/CT scan performed. Four cause-specific Cox regression models were built for the hazard ratios (HR) of recurrence in T-, N-, M-site, and death with no evidence of disease (NED), respectively. The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes. A competing risk analysis was performed and absolute risk estimates were estimated using the Aalen-Johansen method.RESULTS: Overall, 441 patients were included. Thirty-four patients had T-site recurrence, 31 N-site recurrence, 32 M-site recurrence, and 52 patients had death NED as event. Nodal FDG uptake had a significant impact on N- and M-site recurrence, with HRs of 2.13 (CI 1.20-3.77) and 2.18 (CI 1.16-4.10). The individual prognostication of absolute risk of the four events for any given patient can be assessed in the online tool (https://rasmussen.shinyapps.io/OPSCCmodelFDG_PET/).CONCLUSION: High nodal FDG uptake increases the risk of N- and M-site recurrence in patients with OPSCC in a competing risk scenario. The reported results are available in an easy applicable online tool and can help identify relevant candidates for future trials testing treatment approaches.",
author = "Jensen, {Jakob Schmidt} and Christensen, {Julie Thor} and Katrin H{\aa}kansson and Martin Zamani and Vogelius, {Ivan R} and Johan L{\"o}fgren and Fischer, {Babara Malene} and Jeppe Friborg and {von Buchwald}, Christian and Rasmussen, {Jacob H{\o}ygaard}",
year = "2020",
doi = "10.1007/s00259-019-04572-5",
language = "English",
volume = "47",
pages = "1039–1045",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer",

}

RIS

TY - JOUR

T1 - High nodal FDG uptake increases risk of distant metastasis in patients with oropharyngeal squamous cell carcinoma

AU - Jensen, Jakob Schmidt

AU - Christensen, Julie Thor

AU - Håkansson, Katrin

AU - Zamani, Martin

AU - Vogelius, Ivan R

AU - Löfgren, Johan

AU - Fischer, Babara Malene

AU - Friborg, Jeppe

AU - von Buchwald, Christian

AU - Rasmussen, Jacob Høygaard

PY - 2020

Y1 - 2020

N2 - BACKGROUND: The purpose of this study was to investigate if FDG uptake metrics in primary tumor and lymph node metastases in patients with oropharyngeal squamous cell carcinoma (OPSCC) has a prognostic value beyond UICC8 staging in a multiple endpoint model.METHODS: Patients with OPSCC treated with primary radiotherapy at Rigshospitalet in the period 2010-2017 were included. All patients had a pretreatment FDG PET/CT scan performed. Four cause-specific Cox regression models were built for the hazard ratios (HR) of recurrence in T-, N-, M-site, and death with no evidence of disease (NED), respectively. The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes. A competing risk analysis was performed and absolute risk estimates were estimated using the Aalen-Johansen method.RESULTS: Overall, 441 patients were included. Thirty-four patients had T-site recurrence, 31 N-site recurrence, 32 M-site recurrence, and 52 patients had death NED as event. Nodal FDG uptake had a significant impact on N- and M-site recurrence, with HRs of 2.13 (CI 1.20-3.77) and 2.18 (CI 1.16-4.10). The individual prognostication of absolute risk of the four events for any given patient can be assessed in the online tool (https://rasmussen.shinyapps.io/OPSCCmodelFDG_PET/).CONCLUSION: High nodal FDG uptake increases the risk of N- and M-site recurrence in patients with OPSCC in a competing risk scenario. The reported results are available in an easy applicable online tool and can help identify relevant candidates for future trials testing treatment approaches.

AB - BACKGROUND: The purpose of this study was to investigate if FDG uptake metrics in primary tumor and lymph node metastases in patients with oropharyngeal squamous cell carcinoma (OPSCC) has a prognostic value beyond UICC8 staging in a multiple endpoint model.METHODS: Patients with OPSCC treated with primary radiotherapy at Rigshospitalet in the period 2010-2017 were included. All patients had a pretreatment FDG PET/CT scan performed. Four cause-specific Cox regression models were built for the hazard ratios (HR) of recurrence in T-, N-, M-site, and death with no evidence of disease (NED), respectively. The following variables were included: T-, N-stage, p16 status, metabolic tumor volume, and FDG uptake in both primary tumor and lymph nodes. A competing risk analysis was performed and absolute risk estimates were estimated using the Aalen-Johansen method.RESULTS: Overall, 441 patients were included. Thirty-four patients had T-site recurrence, 31 N-site recurrence, 32 M-site recurrence, and 52 patients had death NED as event. Nodal FDG uptake had a significant impact on N- and M-site recurrence, with HRs of 2.13 (CI 1.20-3.77) and 2.18 (CI 1.16-4.10). The individual prognostication of absolute risk of the four events for any given patient can be assessed in the online tool (https://rasmussen.shinyapps.io/OPSCCmodelFDG_PET/).CONCLUSION: High nodal FDG uptake increases the risk of N- and M-site recurrence in patients with OPSCC in a competing risk scenario. The reported results are available in an easy applicable online tool and can help identify relevant candidates for future trials testing treatment approaches.

U2 - 10.1007/s00259-019-04572-5

DO - 10.1007/s00259-019-04572-5

M3 - Journal article

C2 - 31720757

VL - 47

SP - 1039

EP - 1045

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -

ID: 236321084